GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep back to markets around the globe. | As GSK's Blenrep makes its return to ...

In briefing documents released ahead of an Advisory Committee meeting this week, FDA staffers cited safety risks related to a ...

The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug ...

PDUFA date nears for GSK plc’s Blenrep (belantamab mafodotin), the U.S. FDA’s Oncologic Drugs Advisory Committee will decide July 17 on whether available data justify the return to market of the ...

Recent developments illustrate dynamic shifts in the healthcare sector. Trump's spending bill is anticipated to challenge ...

A quiet shift with potentially big implications for cancer drug access is underway in the UK. In June, the country’s health ...

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday authorized GSK plc’s (NYSE:GSK) Blenrep. Blenrep is approved for the treatment of adults with multiple myeloma ...

The Blenrep comeback continues for GSK. The blood cancer treatment, which was once pulled off the market, was found to help patients live longer in a Phase 3 clinical trial, the results of which were ...

Blenrep plus Velcade and dexamethasone significantly improves overall survival in relapsed/refractory multiple myeloma compared to Darzalex-based regimens. The DREAMM-7 trial met its secondary ...

GSK has great expectations for its BCMA-directed cancer drug Blenrep, but a failed phase 3 trial in relapsed or refractory multiple myeloma has raised doubts about its prospects – and even the ...

The MAA for the Blenrep combo was supported by interim results from the phase III DREAMM-7 and DREAMM-8 studies, both of which met their primary endpoints of progression-free survival (PFS).

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday authorized GSK plc’s (NYSE:GSK) Blenrep. Blenrep is approved for the treatment of adults with multiple myeloma ...